Viewing Study NCT02741557

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:31 PM
Ignite Modification Date: 2026-01-05 @ 7:34 PM
Study NCT ID: NCT02741557
Status: COMPLETED
Last Update Posted: 2019-07-15
First Post: 2016-04-14
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)
Sponsor: ViiV Healthcare
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Infection, Human Immunodeficiency Virus View
None HIV Infections View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Fixed-dose Combination (FDC) View
None Bioequivalence View
None Dolutegravir View
None Rilpivirine View